DCC-3014 for Sarcoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Sarcoma+8 More
DCC-3014 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug combo to see if it's safe for people with advanced sarcomas.

Eligible Conditions
  • Sarcoma
  • Malignant Fibrous Histiocytoma
  • Myxofibrosarcoma
  • RNA-Binding Protein FUS
  • High Grade Sarcoma
  • Leiomyosarcoma
  • Advanced Sarcoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Maximum tolerated dose
48 weeks
Overall Response Rate

Trial Safety

Safety Progress

1 of 3

Side Effects for

Single Arm-arm Phase II Study of Avelumab
60%Infusion related reaction
40%Nausea
40%Fatigue
40%Diarrhea
33%Constipation
27%Anorexia
27%Fall
27%Abdominal pain
20%Aspartate aminotransferase increased
20%Dyspnea
20%Chills
20%Creatinine increased
20%Generalized muscle weakness
20%Oral pain
20%Alanine aminotransferase increased
20%Hypocalcemia
13%Cough
13%Anemia
13%Weight loss
13%Fever
13%Dyspepsia
13%Localized edema
13%Back pain
13%Dizziness
7%Pain
7%Confusion
7%Myalgia
7%Hypoxia
7%Flank pain
7%Skin and subcutaneous tissue disorders - Other, Specify: LEFT NOSTRIL SCAB
7%Skin and subcutaneous tissue disorders - Other, Specify: RASH LEFT KNEE, MACULO-PAPULAR
7%Pain in extremity
7%Hyperglycemia
7%Rash maculo-papular
7%Gastrointestinal disorders - Other, Specify: TOOTH FRACTURE
7%Glucose intolerance
7%Surgical and medical procedures - Other Specify; Brain mass removal
7%Dehydration
7%Urinary incontinence
7%Arthralgia
7%Urine discoloration
7%Urinary urgency
7%Respiratory, thoracic and mediastinal disorders - Other, Specify: YAWNING
7%Pain of skin
7%Pruritus
7%Acute kidney injury
7%Thromboembolic event
7%Delirium
7%Syncope
7%Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other Specify; Brain mets
7%Hypothyroidism
7%Atrial fibrillation
7%Eye disorders - Other, Specify: DIPLOPIA
7%Blurred vision
7%Vomiting
7%Infections and infestations - Other, Specify: C. DIF
7%Malaise
7%Skin infection
7%Hyperkalemia
7%Encephalopathy
7%Restlessness
7%Alkaline phosphatase increased
7%Musculoskeletal and connective tissue disorder - Other, Specify: GROIN STRAIN
7%Hypokalemia
7%Buttock pain
7%Urinary retention
7%Skin and subcutaneous tissue disorders - Other, Specify: WOUND ON BACK
7%Tumor pain
7%Nervous system disorders - Other, Specify: CAUDA EQUINA
7%Tremor
7%Surgical and medical procedures - Other, Specify: RIGHT PERCUTANEOUS NEPHROSTOMY TUBE PLACED
7%Nail discoloration
7%Skin and subcutaneous tissue disorders - Other, Specify: ABRASION RIGHT ELBOW
7%Skin and subcutaneous tissue disorders - Other, Specify: MONS PUBIS (HERPES)
7%Flushing
7%Memory impairment
7%Fracture
7%Investigations - Other, Specify: POSITIVE FOR BLOOD IN STOOL
7%Pericarditis
7%Neck pain
7%Blood bilirubin increased
7%Bloating
7%Hyponatremia
7%Sinus bradycardia
7%Musculoskeletal and connective tissue disorder - Other, Specify: MUSCLE CRAMPS
This histogram enumerates side effects from a completed 2020 Phase 2 trial (NCT03179410) in the Single Arm-arm Phase II Study of Avelumab ARM group. Side effects include: Infusion related reaction with 60%, Nausea with 40%, Fatigue with 40%, Diarrhea with 40%, Constipation with 33%.

Trial Design

1 Treatment Group

Advanced High-grade Sarcoma
1 of 1

Experimental Treatment

32 Total Participants · 1 Treatment Group

Primary Treatment: DCC-3014 · No Placebo Group · Phase 1

Advanced High-grade SarcomaExperimental Group · 2 Interventions: DCC-3014, Avelumab · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Avelumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,823 Previous Clinical Trials
584,452 Total Patients Enrolled
63 Trials studying Sarcoma
14,404 Patients Enrolled for Sarcoma
Sandra D'Angelo, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
160 Total Patients Enrolled
2 Trials studying Sarcoma
118 Patients Enrolled for Sarcoma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be aged 18 years or older at the time of informed consent.
You are capable, willing, and able to provide written informed consent/assent.
You are willing to comply with clinical trial instructions and requirement, including mandatory biopsies.
You have a histologically confirmed metastatic and/or locally advanced high grade sarcoma.
You have an adequate performance status.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 14th, 2021

Last Reviewed: November 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.